Last Updated:
First Published:
Pfizer said revenue should come in at the lower end of its guidance for this year, while it expects less revenue in 2026 than in 2025, as the drugmaker’s efforts to remake its business continue to play out.
The company’s stock
PFE was down about 3.7% on Tuesday, even as analysts outlined their support for Pfizer’s plan.
